Chávez-Tapia NC, Uribe M, López E

Language: Spanish
References: 72
Page: 333-339
PDF size: 96.36 Kb.

ABSTRACT

Cardiopulmonar complications in chronic liver diseases were described 100 years ago. Altough both hepatopulmonary síndrome and portopulmonary hypertension originates from liver damage, clinical findings and diagnosis are very different. These complications are important due to the highly deleterous impact on disease evolution and prognosis. Currently, there is not an ideal treatment for these diseases and liver transplantation should be adequately evaluated. In this review we analyze the most important issues on hepatopulmonary síndrome and portopulmonary hypertension. These complications,under the cornerstone of portal hypertension are characterized by pulmonary constriction and dilatation, respectively.

REFERENCES

1. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005;4:52-55.

2. NIH. PubMed. Vol. 2006: National Library of Medicine, 2006.

3. Fluckiger M. Vorkommen von trommelschlägelförmigen Fingerendphalangen ohne chronische Veränderungen an der Lungen oder am Herzen. Wien Med Wschr 1884;34:1457.

4. Rich S. Primary pulmonary hypertension: executive summary from the world symposium on primary pulmonary hypertension 1998. Geneva: World Health Organization, 1998.

5. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-441.

6. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.

7. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994;105:37S-41S.

8. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-551.

9. Portmann B, Stewart S, Higenbottam TW, Clayton PT, Lloyd JK, Williams R. Nodular transformation of the liver associated with portal and pulmonary arterial hypertension. Gastroenterology 1993;104:616-621.

10. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-498.

11. Hiyama E. [Pulmonary vascular changes after portasystemic shunt operation in rats]. Nippon Geka Gakkai Zasshi 1989;90:874-885.

12. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22:405-418.

13. Higenbottam TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest 1998;114:72S-79S.

14. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-E11.

15. Tokiwa K, Iwai N, Nakamura K, Shiraishi I, Hayashi S, Onouchi Z. Pulmonary hypertension as a fatal complication of extrahepatic portal hypertension. Eur J Pediatr Surg 1993;3:373-375.

16. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L46-52.

17. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-1238.

18. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Jr., Gaine SP, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98:1400-1406.

19. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112:980-986.

20. Chan T, Palevsky HI, Miller WT. Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. AJR Am J Roentgenol 1988;151:909-914.

21. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468.

22. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120-126.

23. Ota K, Shijo H, Kokawa H, Kubara K, Kim T, Akiyoshi N, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995;10:198-204.

24. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T, et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988;8:850-854.

25. Ribas J, Angrill J, Barbera JA, Garcia-Pagan JC, Roca J, Bosch J, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999;13:210-212.

26. Uchiyama H, Soejima Y, Taketomi A, Yoshizumi T, Harada N, Ijichi H, et al. Successful adult-to-adult living donor liver transplantation in a patient with moderate to severe portopulmonary hypertension. Liver Transpl 2006;12:481-484.

27. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr 2005;41:466-468.

28. Kato H, Katori T, Nakamura Y, Kawarasaki H. Moderate-term effect of epoprostenol on severe portopulmonary hypertension. Pediatr Cardiol 2003;24:50-53.

29. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 2000;75:625-630.

30. Benza RL, Tallaj JA, Rayburn BK, Foley BA, Bourge RC. Safety and efficacy of treprostinil in cirrhosisrelated pulmonary artery hypertension. Hepatology 2003;38:A530.

31. Halank M, Marx C, Usicenko S, Opitz C, Winkler J, Ewert R. Inhaled iloprost for patients with portopulmonary hypertension. Am J Respir Crit Care Med 2003;167:A277.

32. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502.

33. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25:502-508.

34. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-254.

35. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004;24:861-880.

36. Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Deviere J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996;23:982-987.

37. Callejas Rubio JL, Salmeron Escobar J, Gonzalez-Calvin J, Ortego Centeno N. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. Liver Transpl 2006;12:690-691.

38. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005;24:498-500.

39. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945-950.

40. Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rossle M, et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver — results of a pilot study. Aliment Pharmacol Ther 2006;23:121-128.

41. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.

42. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.

43. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005;11:1026-1027.

44. Kennedy TC, Knudson RJ. Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest 1977;72:305-309.

45. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992;47:897-902.

46. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. Chest 1994;105:1528-1537.

47. Gupta D, Vijaya DR, Gupta R, Dhiman RK, Bhargava M, Verma J, et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001;96:3395-3399.

48. De BK, Sen S, Biswas PK, Sanyal R, Jumdar DM, Biswas J. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology 2000;118:192-196.

49. De BK, Sen S, Biswas PK, Mandal SK, Das D, Das U, et al. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology 2002;122:897-903.

50. McFaul RC, Tajik AJ, Mair DD, Danielson GK, Seward JB. Development of pulmonary arteriovenous shunt after superior vena cava-right pulmonary artery (Glenn) anastomosis. Report of four cases. Circulation 1977;55:212-216.

51. Srivastava D, Preminger T, Lock JE, Mandell V, Keane JF, Mayer JE, Jr., et al. Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation 1995;92:1217-1222.

52. Agusti AG, Roca J, Rodriguez-Roisin R, Mastai R, Wagner PD, Bosch J. Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. Am Rev Respir Dis 1989;139:485-491.

53. Martinez GP, Barbera JA, Visa J, Rimola A, Pare JC, Roca J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001;34:651-657.

54. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998;129:375-378.

55. Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003;362:43-44.

56. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994;331:1098.

57. Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 2005;128:328-333.

58. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003;38:556-563.

59. Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002;166:514-517.

60. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003;133:163-169.

61. Martinez G, Barbera JA, Navasa M, Roca J, Visa J, Rodriguez-Roisin R. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999;30:882-889.

62. Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997;72:44-53.

63. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993;104:515-521.

64. Agusti AG, Roca J, Bosch J, Garcia-Pagan JC, Wagner PD, Rodriguez- Roisin R. Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis. Am Rev Respir Dis 1990;142:306-310.

65. Song JY, Choi JY, Ko JT, Bae EJ, Kim HS, Noh CI, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996;97:917-920.

66. Cadranel JL, Milleron BJ, Cadranel JF, Fermand JP, Andrivet P, Brouet JC, et al. Severe hypoxemia-associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. Am Rev Respir Dis 1992;146:526-527.

67. Krowka MJ, Cortese DA. Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bismesylate. Mayo Clin Proc 1987;62:164-173.

68. Maniscalco M, Sofia M, Higenbottam T. Effects of an NO-synthase inhibitor L-NMMA in the hepatopulmonary syndrome. Respiration 2001;68:226.

69. Anel RM, Sheagren JN. Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. Clin Infect Dis 2001;32:E131-136.

70. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995;109:978-983.

71. Hobeika J, Houssin D, Bernard O, Devictor D, Grimon G, Chapuis Y. Orthotopic liver transplantation in children with chronic liver disease and severe hypoxemia. Transplantation 1994;57:224-228.

72. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002;51:853-859.